I see, a MSB reference when it suits. Finally. But if someone (CYP holder) was to reply, and point out:
Comparison was done against approved treatments - Ryoncil is not yet approved.
CYP P2 trial is in patients with High Risk acute GvHD, Ryoncil may be approved in patients with SR-aGvHD - there's a difference, including a time difference when treatment is available to patients, which- if you want to believe J Galipeau - could have a positive impact on treatment outcome.
Ryoncil/remestemcel-L/Prochymal has clinical data in patients with aGvHD and, lets just say it was the start of the whole sub-sub-sub group, that left Ryoncil with SR-aGvHD in pediatric patients (only), also very small patient group in an already very small pool of patients.
there will be tears again no doubt because we talk about MSB on a CYP thread.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)